Barton Investment Management Makes New Investment in Royalty Pharma PLC $RPRX

Barton Investment Management purchased a new stake in Royalty Pharma PLC (NASDAQ:RPRX) in the 1st quarter, HoldingsChannel reports. The fund purchased 18,875 shares of the biopharmaceutical company’s stock, valued at approximately $905,000.

Other institutional investors have also recently made changes to their positions in the company. LM Advisors LLC acquired a new position in shares of Royalty Pharma during the fourth quarter worth approximately $26,000. Blue Trust Inc. increased its stake in Royalty Pharma by 173.4% during the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 437 shares in the last quarter. Lloyd Advisory Services LLC. acquired a new position in Royalty Pharma during the fourth quarter worth $30,000. Private Trust Co. NA raised its holdings in Royalty Pharma by 52.9% during the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 288 shares during the last quarter. Finally, CIBC Private Wealth Group LLC lifted its stake in shares of Royalty Pharma by 66.4% in the fourth quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 446 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Christopher Hite sold 150,000 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $54.40, for a total transaction of $8,160,000.00. Following the completion of the transaction, the executive vice president directly owned 559,399 shares of the company’s stock, valued at $30,431,305.60. This represents a 21.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 9,098 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $55.18, for a total transaction of $502,027.64. Following the transaction, the executive vice president directly owned 9,099 shares of the company’s stock, valued at $502,082.82. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 323,492 shares of company stock valued at $17,160,920. 18.84% of the stock is currently owned by company insiders.

Royalty Pharma Stock Up 0.8%

RPRX opened at $54.69 on Friday. Royalty Pharma PLC has a fifty-two week low of $34.08 and a fifty-two week high of $56.50. The firm has a market capitalization of $31.49 billion, a P/E ratio of 37.20, a PEG ratio of 1.49 and a beta of 0.43. The company’s 50-day moving average is $52.66 and its 200 day moving average is $46.52. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. The business had revenue of $630.58 million during the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. Research analysts expect that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were paid a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date was Friday, May 15th. Royalty Pharma’s payout ratio is presently 63.95%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on RPRX shares. UBS Group lifted their price objective on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. Citigroup upped their target price on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. JPMorgan Chase & Co. raised their price target on shares of Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Morgan Stanley increased their price objective on Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $53.71.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.